Sophia Genetics SA
SOPH4.800USD
+0.200+4.35%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
325.67M시가총액
손실P/E TTM
자세한 내용은 Sophia Genetics SA 회사
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SA 정보
종목 코드 SOPH
회사 이름SOPHiA GENETICS SA
상장일Jul 23, 2021
CEOCamblong (Jurgi)
직원 수423
유형Ordinary Share
회계 연도 종료Jul 23
주소La Piece 12
도시ROLLE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Switzerland
우편 번호CH-1180
전화41216941060
웹사이트https://www.sophiagenetics.com/
종목 코드 SOPH
상장일Jul 23, 2021
CEOCamblong (Jurgi)
Sophia Genetics SA의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+194164.00%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+48309.00%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-17644.00%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+48309.00%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+59409.00%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+66596.00%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
39.60K
-2144.00%
Mr. Daan Van Well
Mr. Daan Van Well
Chief Legal and Compliance Officer
Chief Legal and Compliance Officer
--
--
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
--
--
Dr. Tomer Berkovitz, Ph.D.
Dr. Tomer Berkovitz, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+194164.00%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+48309.00%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-17644.00%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+48309.00%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+59409.00%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+66596.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
Rest of EMEA
6.63M
34.09%
France
3.12M
16.01%
United States
2.62M
13.45%
Italy
2.51M
12.89%
Spain
1.46M
7.48%
기타
3.13M
16.08%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Feb 1
마지막 업데이트: Sun, Feb 1
주주
주주 유형
주주
주주
비율
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
기타
61.13%
주주
주주
비율
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
기타
61.13%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
16.43%
Venture Capital
13.08%
Family Office
10.36%
Investment Advisor
8.51%
Individual Investor
6.43%
Hedge Fund
1.06%
Bank and Trust
0.46%
Research Firm
0.06%
Pension Fund
0.03%
기타
43.58%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
81
26.90M
39.65%
-12.60M
2025Q3
76
26.89M
39.64%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Alychlo NV
6.99M
10.31%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.01%
--
--
Sep 30, 2025
aMoon Fund
5.51M
8.12%
+577.36K
+11.70%
Feb 15, 2025
Akre Capital Management, LLC
3.72M
5.48%
--
--
Sep 30, 2025
Balderton Capital (UK) LLP
3.36M
4.96%
--
--
Feb 15, 2025
Camblong (Jurgi)
2.65M
3.91%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.25%
--
--
Sep 30, 2025
Alta Wealth Advisors LLC
1.41M
2.08%
+1.41M
--
Sep 30, 2025
Principal Global Investors (Equity)
1.39M
2.05%
-8.95K
-0.64%
Sep 30, 2025
Ossipow (Vincent)
443.81K
0.65%
+48.31K
+12.21%
Feb 15, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
비율0%
Fidelity Nasdaq Composite Index ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
